Investors with a lot of money to spend have taken a bearish stance on Moderna MRNA.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 8 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 75%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $151,677, and 4 are calls, for a total amount of $270,022.
Expected Price Movements
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $130.0 for Moderna during the past quarter.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $50.0 to $130.0 over the preceding 30 days.
Moderna Call and Put Volume: 30-Day Overview
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MRNA | CALL | SWEEP | BEARISH | 04/19/24 | $95.00 | $140.8K | 756 | 223 |
| MRNA | CALL | SWEEP | BEARISH | 01/19/24 | $70.00 | $64.1K | 570 | 71 |
| MRNA | PUT | SWEEP | BULLISH | 06/21/24 | $130.00 | $49.5K | 1.2K | 0 |
| MRNA | PUT | SWEEP | BULLISH | 01/19/24 | $80.00 | $49.2K | 3.3K | 113 |
| MRNA | CALL | TRADE | NEUTRAL | 01/19/24 | $70.00 | $38.9K | 570 | 55 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Having examined the options trading patterns of Moderna, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Current Position of Moderna
- Currently trading with a volume of 1,359,343, the MRNA's price is down by -0.74%, now at $79.36.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 76 days.
What The Experts Say On Moderna
In the last month, 2 experts released ratings on this stock with an average target price of $86.0.
- An analyst from Canaccord Genuity has revised its rating downward to Hold, adjusting the price target to $82.
- An analyst from JP Morgan persists with their Neutral rating on Moderna, maintaining a target price of $90.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
